- Home
- BTAI
as 07-26-2024 4:00pm EST
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 41.3M | IPO Year: | 2018 |
| Target Price: | $6.00 | AVG Volume (30 days): | 696.6K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $10.09 | Next Earning Date: | 08-12-2024 |
| Revenue: | $1,756,000 | Revenue Growth: | 202.24% |
| Revenue Growth (this year): | 131.59% | Revenue Growth (next year): | 209.79% |
Stock Insider Trading Activity of BioXcel Therapeutics Inc. (BTAI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wiley Matthew T. | BTAI | Chief Commercial Officer | Jun 15 '24 | Sell | $1.26 | 244 | $308.10 | 3,498 | SEC Form 4 |
| Rodriguez Javier | BTAI | See Remarks | Jun 14 '24 | Sell | $1.26 | 361 | $456.02 | 8,394 | SEC Form 4 |
| Steinhart Richard I | BTAI | Chief Financial Officer | Jun 14 '24 | Sell | $1.26 | 372 | $469.54 | 5,476 | SEC Form 4 |
| Mehta Vimal | BTAI | CEO and President | Jun 14 '24 | Sell | $1.28 | 2,134 | $2,738.99 | 47,539 | SEC Form 4 |
| O'Neill Vincent | BTAI | See Remarks | Jun 14 '24 | Sell | $1.29 | 155 | $199.17 | 3,524 | SEC Form 4 |
| Mehta Vimal | BTAI | CEO and President | Jun 4 '24 | Sell | $1.63 | 126,014 | $205,516.23 | 7,811,515 | SEC Form 4 |
| Mehta Vimal | BTAI | CEO and President | Jun 4 '24 | Sell | $1.58 | 126,014 | $199,618.78 | 7,685,501 | SEC Form 4 |
| Wiley Matthew T. | BTAI | CHIEF COMMERCIAL OFFICER | Mar 15 '24 | Sell | $2.64 | 1,008 | $2,656.18 | 2,992 | SEC Form 4 |
| O'Neill Vincent | BTAI | See Remarks | Mar 14 '24 | Sell | $2.62 | 165 | $432.48 | 5,408 | SEC Form 4 |
| Mehta Vimal | BTAI | CEO and President | Mar 14 '24 | Sell | $2.62 | 829 | $2,171.98 | 48,003 | SEC Form 4 |
| Mehta Vimal | BTAI | CEO and President | Mar 14 '24 | Sell | $2.62 | 4,439 | $11,651.04 | 43,564 | SEC Form 4 |
| Rodriguez Javier | BTAI | See Remarks | Mar 14 '24 | Sell | $2.64 | 1,012 | $2,667.43 | 7,672 | SEC Form 4 |
| Yocca Frank | BTAI | Chief Scientific Officer | Mar 14 '24 | Sell | $2.64 | 1,067 | $2,811.54 | 12,763 | SEC Form 4 |
| Steinhart Richard I | BTAI | Chief Financial Officer | Mar 14 '24 | Sell | $2.64 | 1,069 | $2,816.81 | 4,765 | SEC Form 4 |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
BioXcel Therapeutics Shares Rise After Preliminary Q2 Revenue Exceeds Estimates
GlobeNewswire
11 days ago
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
GlobeNewswire
a month ago
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
CNW Group
2 months ago
Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024
ACCESSWIRE
2 months ago
Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
Business Insider
2 months ago
Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies
GlobeNewswire
2 months ago
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
Motley Fool
2 months ago
Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger
Compare BTAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.